Erick Gamelin serves as Executive at Acrivon Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Erick Gamelin has executed 7 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Nov 14, 2025 involved selling 403 shares valued at $903.
Erick Gamelin currently holds 15,283 shares of Acrivon Therapeutics, Inc. (ACRV), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Erick Gamelin has been a net neutral trader of ACRV stock. They have purchased $0 and sold $0 worth of shares.
Erick Gamelin's most recent insider trade was on Nov 14, 2025, when they sold 403 shares at $2.24 per share.
Get notified when new Form 4 filings are submitted
| $1.39 |
| Discretionary |
| Aug 14, 2024 | ACRV | $2.8K | Payment | 402 | $7.02 | Discretionary |
| May 14, 2024 | ACRV | $3.4K | Payment | 402 | $8.36 | Discretionary |
| Feb 14, 2024 | ACRV | $1.6K | Payment | 468 | $3.40 | Discretionary |
| Nov 14, 2023 | ACRV | $7.1K | Payment | 1,395 | $5.08 | Discretionary |
| Nov 14, 2022 | ACRV | $0 | Award | 20,030 | $N/A | Discretionary |